Caroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussy in Paris, discusses overall survival (OS) results of a recent study evaluating dabrafenib and trametinib in melanoma.
Dramatic Changes in the RCC Landscape Underscore Importance of Molecular Profiling
June 8th 2023In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.
Read More
Fianlimab Plus Cemiplimab Shows Efficacy in PD-1–Pretreated Metastatic Melanoma
June 5th 2023In the combination of fianlimab and cemiplimab, we showed a consistent and reproducible high clinical activity in 3 independent cohorts of patients who were naive to anti–PD-1 in the advanced melanoma setting, says Omid Hamid, MD.
Read More
2 Clarke Drive
Cranbury, NJ 08512